The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Burden of Illness in Type 2 Diabetes Mellitus
Open accessAbstract
An estimated 30.2 million Americans have diabetes, and this number is expected to increase based on trends over recent decades and compounded by an aging U.S. POPULATION: As reviewed in this article, type 2 diabetes mellitus (T2DM) is associated with impaired health-related quality of life (HRQoL) and with a substantial socioeconomic burden. Compared with individuals without T2DM, those with T2DM have worse HRQoL, greater decrements in HRQoL over time, and possibly greater depressive symptomology. Diabetes-related complications and comorbidities (e.g., obesity and cardiovascular disease) are associated with worse HRQoL. Hypoglycemic episodes are associated with reduced HRQoL and greater levels of depression; they can also interfere with social and occupational activities. In turn, low HRQoL can be a driver for poor glycemic control. In 2012, the total estimated cost associated with diagnosed diabetes in the United States was $245 billion. Factors contributing to increased health care resource utilization and costs in patients with T2DM include medical comorbidities, diabetes-related complications, inadequate glycemic control, and hypoglycemic episodes. Readmission is a key driver of hospital-related costs and is more common among elderly patients with T2DM. Elderly patients with T2DM represent a particularly vulnerable population given that these patients may have varying degrees of physical and mental comorbidities that can increase their risk of hypoglycemia, falls, and depression. This review demonstrates that T2DM imposes a considerable burden on both the individual and society. Treatment strategies should consider the effects of treatment on HRQoL and on outcomes (e.g., complications and hypoglycemia) that affect both HRQoL and costs. Management strategies that maximize HRQoL while minimizing the risk of hypoglycemia and other treatment-related complications are particularly critical in the elderly. DISCLOSURES: This supplement was funded by Novo Nordisk. Cannon reports speaker fees and owns stock in Novo Nordisk. Handelsman reports research grants from Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Grifols, Janssen, Lexicon, Merck, Novo Nordisk, Regeneron, and Sanofi; speaker fees from Amarin, Amgen, AstraZeneca, Boehringer Ingelheim-Lilly, Janssen, Merck, Novo Nordisk, Regeneron, and Sanofi; and has served in advisory capacity to Amarin, Amgen, AstraZeneca, Boehringer Ingelheim, Eisai, Intarcia, Janssen, Lilly, Merck, Merck-Pfizer, Novo Nordisk, Regeneron, and Sanofi. Heile reports speaker fees from and has served as advisor to Novo Nordisk. Shannon reports consultant and speaker fees from Novo Nordisk and Boehringer Ingelheim-Lilly Alliance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The importance of weight management in type 2 diabetes mellitus
Wilding, J. P. H. (2014) · International Journal of Clinical Practice · doi:10.1111/ijcp.12384 · Cited by 314
Ul‐Haq, Z., Mackay, D. F., Fenwick, E., & Pell, J. P. (2013) · Obesity · doi:10.1002/oby.20107 · Cited by 311
Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006–2013
Lipska, K. J., Yao, X., Herrin, J., McCoy, R. G., Ross, J. S., Steinman, M. A., Inzucchi, S. E., Gill, T. M., Krumholz, H. M., & Shah, N. D. (2017) · Diabetes Care · doi:10.2337/dc16-0985 · Cited by 306
Depression in diabetes: have we been missing something important?
Gonzalez, J. S., Fisher, L., & Polonsky, W. H. (2011) · Diabetes Care · doi:10.2337/dc10-1970 · Cited by 302
Diabetes mellitus and stroke: A clinical update
Tun, N. N., Arunagirinathan, G., Munshi, S. K., & Pappachan, J. M. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.235 · Cited by 177
Lopez, J., Annunziata, K., Bailey, R., Morisky, D. E., & Rupnow, M. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s58813 · Cited by 96
Cited by
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s005 · Cited by 362
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s005 · Cited by 445
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Eichorst, B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s005 · Cited by 305
Association between Systemic Immune-Inflammation Index and Diabetic Depression
Wang, J., Zhou, D., Dai, Z., & Li, X. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s285000 · Cited by 238
The Changing Nature of Mortality and Morbidity in Patients with Diabetes
Pearson-Stuttard, J., Buckley, J., Cicek, M., & Gregg, E. W. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.001 · Cited by 48
Metadata
- Authors
- Cannon, A., Handelsman, Y., Heile, M., & Shannon, M.
- Venue
- Journal of Managed Care & Specialty Pharmacy
- Publisher
- Academy of Managed Care Pharmacy
- Published
- 2018-09
- Volume
- 24
- Issue
- 9-a Suppl
- Pages
- S5-S13
- ISSN
- 2376-0540 (ISSN-L)
- 2376-1032
- OpenAlex
- W2889278708
- Cited by
- 225
- References
- 6
- FWCI
- 10.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Burden of Illness in Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.18553/jmcp.2018.24.9-a.s5
- The paper
- Cannon, A., Handelsman, Y., Heile, M., & Shannon, M. (2018). Burden of Illness in Type 2 Diabetes Mellitus. Journal of Managed Care & Specialty Pharmacy. https://doi.org/10.18553/jmcp.2018.24.9-a.s5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.